Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02549638 · ClinicalTrials.gov registry record
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 22
- Enrollment target
NCT02549638: Clinical Trial study, sponsored by Mayo Clinic.
NCT02549638 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02549638 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The study will utilize both retrospective and prospective data collection from patients that already had a bronchoscopy and lung resection or will have a bronchoscopy and lung resection for squamous cell carcinoma. The investigators plan to prospectively collect 5 bronchoscopic biopsies, 10ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria.
Primary Outcome
The aim of this study is to identify and characterized recurrent genomic alteration found in invasive squamous cell carcinoma that are present in the precursor airway epithelial tissues but absent in normal tissues examined from samples taken during a lung procedure.
Interventions
- GENETIC DNA Extraction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-04-08 |
| Est. Completion | 2020-04-23 |
Why NCT02549638 stopped before completion
NCT02549638 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which DNA Extraction is the first listed.
NCT02549638 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02549638 about?
NCT02549638 is a clinical study titled "Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma". The study will utilize both retrospective and prospective data collection from patients that already had a bronchoscopy and lung resection or will have a bronchoscopy and lung resection for squamous cell carcinoma. The investigators plan to prospectively collect 5 bronchoscopic biopsies, 10ml blood ...
What is the current status of trial NCT02549638?
This trial is currently terminated. The enrollment target is 22 participants. The study started on 2015-04-08. Estimated completion is 2020-04-23.
What interventions are being tested in trial NCT02549638?
The interventions under investigation include: DNA Extraction (GENETIC).
Who is sponsoring clinical trial NCT02549638?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI